RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
Stopped early
Conditions studied: Liver Cancer
In brief
This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with TheraSphere® in a real-life setting from multiple centers globally. The absorbed dose to tumor and normal tissue will be calculated using the Simplicit90Y™ software in the subgroup of hepatocellular carcinoma (HCC) participants.
Key facts
- Study ID
- NCT03516695
- Run by
- Boston Scientific Corporation
- People needed
- 95
- Starts
- 2018-02-23
- Expected to finish
- 2018-12-12
- Last updated by the study team
- 2021-04-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participant is ≥ 18 years of age
- Participant has confirmed liver cancer
- Participant is able to provide informed consent according to local requirements/law
- Participant has a life expectancy of ≥ 3 months
- Participant is scheduled to receive TheraSphere® treatment
You may not qualify if…
- Participant who has previously received Y90 microspheres
- Participant who has consented to participate in a BTG-sponsored clinical study that includes TheraSphere® treatment
Where it is running
- UCLA — Los Angeles, California, United States
- University of Miami — Coral Gables, Florida, United States
- Rush University Medical Center — Chicago, Illinois, United States
- Indiana University — Indianapolis, Indiana, United States
- Allina Health System Virginia Piper Cancer Institute — Minneapolis, Minnesota, United States
- Regents of the University of Minnesota — Minneapolis, Minnesota, United States
- New York University School of Medicine — New York, New York, United States
- University of Alberta — Edmonton, Alberta, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.